logo
FLGT_building
According to the complaint, investors learned the truth on Aug. 4, 2022, when Fulgent announced its Q2 2022 financial results and startled investors with its additional disclosure that the SEC was investigating the company’s 2018 – Q1 2020 financial reports and the DOJ was investigating allegations of medically unnecessary laboratory testing, improper billing for laboratory testing, and compensation received or provided in violation of federal and California law

FLGT SHAREHOLDER NOTICE: Hagens Berman, National Trial Attorneys, Encourages Fulgent Genetics ...

Hagens Berman urges Fulgent Genetics, Inc. (NASDAQ: FLGT) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed after Fulgent disclosed the DOJ and SEC are conducting investigations

By Hagens Berman Sobol Shapiro LLP
Published - Oct 31, 2022, 09:59 AM ET
Last Updated - Jul 22, 2024, 05:11 AM EDT

SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Fulgent Genetics, Inc. (NASDAQ: FLGT) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed after Fulgent disclosed the DOJ and SEC are conducting investigations.

Class Period: Mar. 22, 2019 – Aug. 4, 2022
Lead Plaintiff Deadline: Nov. 21, 2022
Visit: www.hbsslaw.com/investor-fraud/FLGT
Contact An Attorney Now: FLGT@hbsslaw.com
844-916-0895

Fulgent Genetics, Inc. (NASDAQ: FLGT) Securities Fraud Class Action:

The litigation focuses on Fulgent’s previously claimed “very strong” and “truly outstanding” financial results.

Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024